## Tao Li

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3615892/publications.pdf

Version: 2024-02-01

		1163117	888059
19	285	8	17
papers	citations	h-index	g-index
19	19	19	545
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review. Hepatology, 2019, 70, 1045-1055.	7.3	93
2	Efficacy and safety of directâ€acting antiviralsâ€based antiviral therapies for hepatitis C virus patients with stage 4â€5 chronic kidney disease: a metaâ€analysis. Liver International, 2017, 37, 974-981.	3.9	68
3	A Beginning or the End? A Meta-analysis to Assess the Diagnostic Accuracy of Transient Elastography for the Prediction of Esophageal Varices. Saudi Journal of Gastroenterology, 2016, 22, 345.	1.1	19
4	Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19. Clinics, 2021, 76, e2604.	1.5	16
5	Varying 10â€year offâ€treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. Journal of Digestive Diseases, 2018, 19, 561-571.	1.5	13
6	Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection. World Journal of Gastroenterology, 2017, 23, 5969.	3.3	12
7	Baseline characteristics and changes of biomarkers in disease course predict prognosis of patients with COVID-19. Internal and Emergency Medicine, 2021, 16, 1165-1172.	2.0	12
8	Abnormal liver-related biomarkers in COVID-19 patients and the role of prealbumin. Saudi Journal of Gastroenterology, 2020, 26, 272.	1.1	9
9	Efficacy and safety of sofosbuvirâ€based interferonâ€free therapies for hepatitis C in liver transplant recipients. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 740-748.	2.8	8
10	Reply. Hepatology, 2019, 70, 1489-1490.	7.3	5
11	Nucleoside/nucleotide analog consolidation therapy in hepatitis B eâ€antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatology Research, 2021, 51, 633-640.	3.4	5
12	Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatology Research, 2017, 47, 1000-1007.	3.4	4
13	Performance of quick sequential organ failure assessment (qSOFA) score for prognosis of heat-related hospitalized patients. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 415-419.	1.6	4
14	Animal naming test for the assessment of minimal hepatic encephalopathy in Asian cirrhotic populations. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101729.	1.5	4
15	Combination Of Biomarkers In Predicting 28-day Mortality For Septic Patients. Journal of the College of Physicians and SurgeonsPakistan: JCPSP, 2018, 28, 672-676.	0.4	4
16	Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World Journal of Gastroenterology, 2021, 27, 1497-1506.	3.3	3
17	Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. Saudi Journal of Gastroenterology, 2018, 24, 30.	1.1	3
18	Efficacy and safety of simeprevir for chronic hepatitis virus C genotype 1 infection: A meta-analysis. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 203-212.	1.5	2

#	Article	IF	CITATIONS
19	Reply. Hepatology, 2019, 69, 1844-1844.	7.3	1